Journal
DRUG RESEARCH
Volume 71, Issue 3, Pages 166-170Publisher
GEORG THIEME VERLAG KG
DOI: 10.1055/a-1296-7935
Keywords
antiviral drugs; drug research; clinical trials
Ask authors/readers for more resources
This review summarizes the clinical trials studying the efficacy and safety of favipiravir in patients with COVID-19, highlighting it as a potential treatment option for the novel coronavirus infection.
A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan, China, at the end of 2019 and then spread rapidly all over the world. However, there are no specific antiviral therapies for COVID-19, using the agents which approved or in development for other viral infections is one of the potentially quickest ways to find treatment for this new viral infection. Favipiravir is an effective agent that acts as a nucleotide analog that selectively inhibits the viral RNA dependent RNA polymerase or causes lethal mutagenesis upon incorporation into the virus RNA. In view of recent studies and discussion on favipiravir, in this mini review we aimed to summarize the clinical trials studying the efficacy and safety of favipiravir in patients with COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available